New design may boost potency of monoclonal antibodies against COVID

Monoclonal antibody drugs are among the few treatments available for COVID, providing a lifeline for those at high risk of severe illness and hospitalization. However, the usefulness of these drugs is limited because they are effective only when they can be administered early in the disease process.

This post was originally published on this site

Lawyers Lookup - LawyersLookup.ca